The pharmaceutical company’s stock is relatively cheap, representing an opportunity for patient value investors.

Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

Eli Lilly (LLY) said a study of its drug Ebglyss showed it was able to improve skin and itch in patients with atopic ...

Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the ...

Key drugs from Johnson & Johnson and Eli Lilly stand to bolster their respective cases in competitive dermatology markets ...

As more Big Pharma companies have launched direct-to-consumer telehealth platforms, lawmakers have raised concerns they might ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

New results show Eli Lilly’s Ebglyss improved skin and itch among patients with moderate-to-severe atopic dermatitis who were previously treated with dupilumab. These results fr ...

Citi raised the firm’s price target on Eli Lilly (LLY) to $1,250 from $1,060 and keeps a Buy rating on the shares following a transfer of ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

On July 1, IUPUI was split into Indiana University Indianapolis and Purdue University in Indianapolis. Purdue’s Indianapolis ...

A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...